RGEN vs. SMMT: Repligen vs. Summit Therapeutics Stock Comparison

November 11, 2026

How do Repligen (RGEN) and Summit Therapeutics (SMMT) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Repligen (RGEN) and Summit Therapeutics (SMMT) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but RGEN is classified in Life Sciences Tools & Services while SMMT is classified in Biotechnology.

Company profile comparison for Repligen (RGEN) and Summit Therapeutics (SMMT)
Profile Item	RGEN	SMMT
Name	Repligen Corporation	Summit Therapeutics Inc.
Country/Region	United States	United States
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Life Sciences Tools & Services	Biotechnology
GICS Sub-Industry	Life Sciences Tools & Services	Biotechnology
Market Capitalization	11.09 billion USD	13.06 billion USD
Currency	USD	USD
Exchange	Nasdaq	Nasdaq
Listing Date	April 29, 1986	March 5, 2015
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

RGEN

SMMT

GSPC

Repligen (RGEN) vs. Summit Therapeutics (SMMT), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Repligen (RGEN) and Summit Therapeutics (SMMT). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Repligen (RGEN) and Summit Therapeutics (SMMT). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Repligen (RGEN) and Summit Therapeutics (SMMT)
Metric	RGEN	SMMT
Total Return (1Y)	23.28%	-2.48%
Total Return (3Y, Annualized)	6.20%	116.18%
Total Return (5Y, Annualized)	-8.41%	26.89%

Risk Profile

Drawdown History

RGEN

SMMT

GSPC

Repligen (RGEN) vs. Summit Therapeutics (SMMT), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Repligen (RGEN) and Summit Therapeutics (SMMT). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Summit Therapeutics (SMMT) reports a negative beta of -1.51, suggesting inverse market sensitivity over the measurement window. That is uncommon for ordinary equities and can reflect commodity-linked or hedge-like exposure, but it can also come from statistical noise. Repligen (RGEN) has a non-negative beta of 1.11.

Risk profile metrics for Repligen (RGEN) and Summit Therapeutics (SMMT)
Metric	RGEN	SMMT
Volatility (1Y, Annualized)	46.73%	75.06%
Beta (5Y)	1.11	-1.51
Max Drawdown (5Y)	-64.67%	-87.64%
Avg. Volume (3M)	1.18M	6.19M

Risk-Adjusted Performance

Risk-Return Positioning

RGEN and SMMT are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Repligen (RGEN) and Summit Therapeutics (SMMT)
Metric	RGEN	SMMT
Sharpe Ratio (1Y)	0.41	-0.09
Sortino Ratio (1Y)	0.60	-0.13

Profitability

ROE (TTM)

Both Repligen (RGEN) at -0.57% and Summit Therapeutics (SMMT) at -220.01% report negative ROE values. Negative ROE can reflect losses or negative shareholders’ equity, so both readings need extra context.

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

-0.57%

Max: 109.18%
Q3: 6.23%
RGEN: -0.57%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

SMMT

Pharmaceuticals, Biotechnology & Life Sciences industry group

-220.01%

Max: 109.18%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%
SMMT: -220.01%

Repligen (RGEN) vs. Summit Therapeutics (SMMT): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Repligen (RGEN) reports a negative net margin of -1.47%, usually indicating a net loss over the period. Meanwhile Summit Therapeutics (SMMT) reports 0.00%, ranking against industry peers normally.

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

-1.47%

Max: 18.05%
Q3: 4.78%
Median: 0.00%
RGEN: -1.47%
Q1: -4.14%
Min: -17.05%

SMMT

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Max: 18.05%
Q3: 4.78%
SMMT: 0.00%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

Repligen (RGEN) vs. Summit Therapeutics (SMMT): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both Repligen (RGEN) at 6.19% and Summit Therapeutics (SMMT) at 0.00% run core operations about as efficiently as their industries’ norm — neither stands out on operating profitability.

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.19%

Max: 83.12%
Q3: 14.77%
RGEN: 6.19%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

SMMT

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Max: 83.12%
Q3: 14.77%
SMMT: 0.00%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

Repligen (RGEN) vs. Summit Therapeutics (SMMT): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Repligen (RGEN) and Summit Therapeutics (SMMT)
Metric	RGEN	SMMT
ROE (TTM)	-0.57%	-220.01%
ROA (TTM)	1.40%	-111.99%
Net Margin (TTM)	-1.47%	0.00%
Operating Margin (TTM)	6.19%	0.00%
Gross Margin (TTM)	53.77%	0.00%

Growth

Revenue Growth

Only one side can be read here: Repligen (RGEN) reports revenue growth of 16.36%, ranked against its industry; Summit Therapeutics (SMMT) has no revenue growth figure this period.

Repligen (RGEN) vs. Summit Therapeutics (SMMT): A comparison of their Revenue Growth across different time periods.

EPS Growth

Neither Repligen (RGEN) nor Summit Therapeutics (SMMT) reports a EPS growth value for this period, so a direct comparison isn't possible.

Repligen (RGEN) vs. Summit Therapeutics (SMMT): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Repligen (RGEN) and Summit Therapeutics (SMMT)
Metric	RGEN	SMMT
Revenue Growth (YoY)	16.36%	--
Revenue Growth (3Y CAGR)	-2.70%	--
EPS Growth (YoY)	--	--
EPS Growth (3Y CAGR)	-35.73%	--

Financial Strength

Current Ratio (MRQ)

Both Repligen (RGEN) at 9.88 and Summit Therapeutics (SMMT) at 5.99 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

9.88

Max: 25.13
Q3: 12.13
RGEN: 9.88
Median: 5.52
Q1: 2.47
Min: 0.10

SMMT

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.99

Max: 25.13
Q3: 12.13
SMMT: 5.99
Median: 5.52
Q1: 2.47
Min: 0.10

Repligen (RGEN) vs. Summit Therapeutics (SMMT): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Both Repligen (RGEN) at 0.33 and Summit Therapeutics (SMMT) at 0.04 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.33

Max: 1.42
Q3: 0.65
RGEN: 0.33
Median: 0.15
Q1: 0.02
Min: 0.00

SMMT

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.04

Max: 1.42
Q3: 0.65
Median: 0.15
SMMT: 0.04
Q1: 0.02
Min: 0.00

Repligen (RGEN) vs. Summit Therapeutics (SMMT): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Repligen (RGEN) and Summit Therapeutics (SMMT)
Metric	RGEN	SMMT
Current Ratio (MRQ)	9.88	5.99
Debt / Equity (MRQ)	0.33	0.04
Net Debt / EBITDA	-1.19	--

Dividends

Dividend Yield (TTM)

Neither Repligen (RGEN) nor Summit Therapeutics (SMMT) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

RGEN: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

SMMT

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

SMMT: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Repligen (RGEN) vs. Summit Therapeutics (SMMT): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Neither Repligen (RGEN) nor Summit Therapeutics (SMMT) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

RGEN: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

SMMT

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

SMMT: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Repligen (RGEN) vs. Summit Therapeutics (SMMT): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Repligen (RGEN) and Summit Therapeutics (SMMT)
Metric	RGEN	SMMT
Dividend Yield (TTM)	0.00%	0.00%
Dividend Payout Ratio (TTM)	0.00%	0.00%

Valuation

P/E Ratio (TTM)

Neither Repligen (RGEN) nor Summit Therapeutics (SMMT) reports a P/E ratio value for this period, so a direct comparison isn’t possible.

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 85.34
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07
RGEN: --

SMMT

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 85.34
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07
SMMT: --

Repligen (RGEN) vs. Summit Therapeutics (SMMT): Neither stock reports P/E ratio, so the chart shows available benchmark boxes without value markers.

P/S Ratio (TTM)

A sales-based read is only available for Repligen (RGEN), whose P/S ratio of 13.77 ranks against industry peers; Summit Therapeutics (SMMT) reports no figure this period.

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

13.77

Max: 58.18
Q3: 25.77
RGEN: 13.77
Median: 7.30
Q1: 3.01
Min: 0.01

SMMT

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 58.18
Q3: 25.77
Median: 7.30
Q1: 3.01
Min: 0.01
SMMT: --

Repligen (RGEN) vs. Summit Therapeutics (SMMT): SMMT does not report P/S ratio, so it has no value marker; RGEN is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/B Ratio (MRQ)

Repligen (RGEN) at 4.70 sits near its industry’s typical P/B ratio, while Summit Therapeutics (SMMT) at 23.13 prices above its benchmark range — SMMT looks rich relative to book.

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.70

Max: 13.53
Q3: 6.54
RGEN: 4.70
Median: 3.25
Q1: 1.69
Min: -5.59

SMMT

Pharmaceuticals, Biotechnology & Life Sciences industry group

23.13

SMMT: 23.13
Max: 13.53
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

Repligen (RGEN) vs. Summit Therapeutics (SMMT): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Repligen (RGEN) and Summit Therapeutics (SMMT)
Metric	RGEN	SMMT
P/E Ratio (TTM)	--	--
P/S Ratio (TTM)	13.77	--
P/B Ratio (MRQ)	4.70	23.13
Free Cash Flow Yield (TTM)	1.01%	-1.64%